NCT00761644 is a Phase 1 clinical trial of Doxil in Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00761644?

NCT00761644 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00761644?

Interventions in NCT00761644: Doxil, Bevacizumab, Temsirolimus.

What condition does NCT00761644 study?

NCT00761644 studies Advanced Cancer.

Is NCT00761644 still recruiting?

NCT00761644 is currently completed. Last updated 11 April 2019.

Last reviewed 2019-04-11 · How we verify

NCT00761644

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Doxil, Bevacizumab and Temsirolimus Trial

Completed Phase 1 Last updated 11 April 2019

What this trial tests

Phase 1 trial testing Doxil in Advanced Cancer in 200 participants. Completed in 28 March 2019.

Timeline

21 August 2008

Primary endpoint
28 March 2019

28 March 2019

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	21 August 2008
Primary completion	28 March 2019
Estimated completion	28 March 2019
Sites	1 location across United States

Drugs / interventions tested

Doxil (doxil) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Temsirolimus (temsirolimus) — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

12 and older, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Garrido-Castro AC, Lin NU, Polyak K. · · 2019 · cited 1061× · PMID 30679171 · DOI 10.1158/2159-8290.cd-18-1177
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
Nedeljković M, Damjanović A. · · 2019 · cited 576× · PMID 31443516 · DOI 10.3390/cells8090957
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F, Wheler JJ, Westin SN, Moulder SL, et al · · 2012 · cited 361× · PMID 22271473 · DOI 10.1200/jco.2011.36.1196
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, et al · · 2011 · cited 290× · PMID 21216929 · DOI 10.1158/1535-7163.mct-10-0994
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
Zhu K, Wu Y, He P, Fan Y, et al · · 2022 · cited 117× · PMID 36010585 · DOI 10.3390/cells11162508
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
Park JH, Ahn JH, Kim SB. · · 2018 · cited 109× · PMID 29765774 · DOI 10.1136/esmoopen-2018-000357
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.
Weigelt B, Downward J. · · 2012 · cited 72× · PMID 22970424 · DOI 10.3389/fonc.2012.00109
Hypoxic Microenvironment and Metastatic Bone Disease.
Hiraga T. · · 2018 · cited 50× · PMID 30423905 · DOI 10.3390/ijms19113523

Verify or expand the search:

Other trials of Doxil

Trials testing the same drug.

NCT01902225 — Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adul · Phase 1 · completed
NCT01736943 — Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia · Phase 2 · completed
NCT00608972 — Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer · Phase 2 · completed

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00761644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 11 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00761644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing